Bosutinib for the treatment of chronic myeloid leukemia.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The pharmacology, pharmacokinetics, efficacy, and safety of the tyrosine kinase inhibitor (TKI) bosutinib in the management of chronic myeloid leukemia (CML) are reviewed.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Am J Health Syst Pharm

Title: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists

Publisher: American Society of Health System Pharmacists

ISSN (Electronic): 1535-2900

ISSN (Print): 1079-2082

Publication date (Electronic): Mar 15 2015

Volume: 72

Issue: 6

Affiliations

[1 ] Vi Doan, Pharm.D., is Postgraduate Year 2 Oncology Pharmacy Resident; Alice Wang, Pharm.D., BCOP, is Clinical Pharmacy Specialist; and Hillary Prescott, Pharm.D., BCOP, is Clinical Pharmacy Specialist, University of Texas MD Anderson Cancer Center, Houston. vpdoan@mdanderson.org.

[2 ] Vi Doan, Pharm.D., is Postgraduate Year 2 Oncology Pharmacy Resident; Alice Wang, Pharm.D., BCOP, is Clinical Pharmacy Specialist; and Hillary Prescott, Pharm.D., BCOP, is Clinical Pharmacy Specialist, University of Texas MD Anderson Cancer Center, Houston.

Article

Publisher Item ID: 72/6/439

DOI: 10.2146/ajhp140221

PubMed ID: 25736937

SO-VID: e7eed5a5-fee9-4d24-afb7-ffa6367a262b

History

Data availability:

Comments

Comment on this article

scite_

Cited by 4

See all cited by